Phase II study of S-1 plus oxaliplatin 130 mg/m 2 in Japanese patients with advanced gastric cancer
ConclusionResults indicated that SOX130 was feasible in Japanese patients with advanced gastric cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Study | Thrombocytopenia